Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.49 |
| ▸ | NAAA | Q02083 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
| ▸ | IDH1 | O75874 | 3/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 2/20 | 0.37 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27009026 | 1.00 | FAAH (0.49) | FAAHNAAAALDH1A1FFAR4IDH1 | |
| SCHEMBL5558778 | 0.89 | ALDH1A1 (0.46) | FAAHNAAAALDH1A1IDH1PPARA | |
| SCHEMBL6442419 | 0.89 | ALDH1A1 (0.46) | FAAHNAAAALDH1A1IDH1PPARA | |
| SCHEMBL8674159 | 0.88 | NAAA (0.43) | FAAHNAAAALDH1A1IDH1HDAC1 | |
| SCHEMBL8007307 | 0.88 | NAAA (0.43) | FAAHNAAAALDH1A1IDH1HDAC1 | |
| SCHEMBL3308447 | 0.88 | GRM5 (0.46) | FAAHNAAAALDH1A1IDH1 | |
| SCHEMBL1750169 | 0.88 | ALDH1A1 (0.55) | FAAHNAAAALDH1A1IDH1PPARA | |
| SCHEMBL3308451 | 0.88 | GRM5 (0.46) | FAAHNAAAALDH1A1IDH1 | |
| SCHEMBL9970285 | 0.88 | GRM5 (0.46) | FAAHNAAAALDH1A1IDH1 | |
| SCHEMBL1750168 | 0.88 | ALDH1A1 (0.55) | FAAHNAAAALDH1A1IDH1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4232431-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LHOTSE BIO INC (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | Lhotse Bio, Inc (US) | 2024-01-18 | — | — | US | disclosed |
| CN-116583501-A | Compounds and compositions for treating conditions associated with LPA receptor activity | 罗特斯生物公司 | 2023-08-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018102-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH LPA RECEPTOR ACTIVITY | LPAR1, LPAR2, LPAR5 | FAAH 136/4885NAAA 857/4885ALDH1A1 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.